June 3 - 6, 2024
Sanofi and Novo Nordisk are battling for market share in an increasingly competitive insulin field. France’s Sanofi has sued Novo over the Danish drugmaker’s marketing materials for Tresiba, alleging that they falsely claimed Sanofi’s competing products—blockbuster Lantus and follow-up Toujeo—won’t be available to many U.S. patients down the line.